ImmunityBio, Inc. (IBRX)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $8.99B
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Latest financial period: June 30, 2026
Filed with the SEC: August 4, 2026
Estimated earnings date: November 3, 2026
Profit #1482 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROA | -157.3% | -158.6% | -84.0% | -101.8% |
Growth #140 of 1484 companies
Payout #1117 of 1484 companies
Safety #1481 of 1484 companies
Price #1421 of 1484 companies
